These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16502534)

  • 1. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
    Whalen J
    Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
    [No Abstract]   [Full Text] [Related]  

  • 2. How NICE may be outflanked.
    Ferner RE; McDowell SE
    BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges in Using MCDA for Reimbursement Decisions on New Medicines?
    Walker A
    Value Health; 2016; 19(2):123-4. PubMed ID: 27021744
    [No Abstract]   [Full Text] [Related]  

  • 4. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationing in the fiscal ice age.
    Klein R
    Health Econ Policy Law; 2010 Oct; 5(4):389-96. PubMed ID: 20565993
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness considerations at NICE.
    Rawlins M; Dillon A
    Lancet; 2008 Oct; 372(9646):1302. PubMed ID: 18929903
    [No Abstract]   [Full Text] [Related]  

  • 7. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
    Steinbrook R
    N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
    [No Abstract]   [Full Text] [Related]  

  • 8. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer drugs offer hope, but at huge expense.
    Berenson A
    N Y Times Web; 2005 Jul; ():A1, C3. PubMed ID: 16075470
    [No Abstract]   [Full Text] [Related]  

  • 10. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease. Three-score years and then?
    Bryan J
    Health Serv J; 1998 Aug; 108(5619):suppl 4-5, 7-8. PubMed ID: 10185456
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 13. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis without treatment as a modifier in health economic assessments.
    Camidge R; Walker A; Oliver JJ; Nussey F; Maxwell S; Jodrell D; Webb DJ
    BMJ; 2005 Jun; 330(7504):1382-4. PubMed ID: 15947403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pfizer to make palbociclib temporarily free on NHS.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
    [No Abstract]   [Full Text] [Related]  

  • 16. NHS spending on drugs is frozen for two years under price deal.
    Wise J
    BMJ; 2013 Nov; 347():f6731. PubMed ID: 24201064
    [No Abstract]   [Full Text] [Related]  

  • 17. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the aim of the English health care system to maximize QALYs?
    Shah K; Praet C; Devlin N; Sussex J; Appleby J; Parkin D
    J Health Serv Res Policy; 2012 Jul; 17(3):157-63. PubMed ID: 22767891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New NICE criteria for drug access.
    Fricker J
    Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.